Evidence Hub

Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide

Iskander M, Wadhwa M, Kim Y, Singh N, Pathak P

Cureus, 2025

2 citations

Abstract

Obesity has become a significant global challenge, highlighting the need for effective weight loss strategies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising solution, with tirzepatide gaining significant popularity for its efficacy in promoting weight loss. This case report highlights a 57-year-old male patient with type 2 diabetes on a low dose of tirzepatide who initially presented with severe abdominal pain and vomiting, with symptoms resembling those of acute functional gastric outlet obstruction. Despite initial suspicion of an anatomical obstruction, no abnormalities were found on esophagogastroduodenoscopy. The symptoms resolved following the discontinuation of tirzepatide, suggesting a causative link. This case underscores the importance of physician awareness and patient education regarding potential severe gastrointestinal side effects associated with tirzepatide, even at low doses.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free